Treating statin-intolerant patients

References

• Baigent C Keech A Kearney PM Cholesterol Treatment Trialists’ (CTT) Collaborators Cholesterol Treatment Trialists (CTT) Collaborators: efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomized trials of statins Lancet 2005 366 9493 1267 1278 16214597
   PubMed Web of Science ®Google Scholar
• Armitage J The safety of statins in clinical practice Lancet 2007 370 9601 1781 1790 17559928
   PubMed Web of Science ®Google Scholar
• Gotto AMG Statins, cardiovascular disease, and drug safety Am J Cardiol 2006 97 8A 3C 5C 16675316
   PubMed Web of Science ®Google Scholar
• McKenney JM Davidson MH Jacobson TA Guyton JR Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 2006 97 8A 89C 94C
   PubMed Web of Science ®Google Scholar
• Silva MA Swanson AC Gandhi PJ Tataronis GR Statin-related adverse events: a meta-analysis Clin Ther 2006 28 1 26 35 16490577
   PubMed Web of Science ®Google Scholar
• Law M Rudnicka AR Statin safety: a systematic review Am J Cardiol 2006 97 8A 52C 60C
   PubMed Web of Science ®Google Scholar
• Harper CR Jacobson TA Evidence-based management of statin myopathy Curr Atheroscler Rep 2010 12 5 322 330 20628837
   PubMed Web of Science ®Google Scholar
• Davidson M Clark J Glass L Kanumalla A Statin safety: an appraisal from the adverse event reporting system Am J Cardiol 2006 97 Suppl 1 32C 43C
   Web of Science ®Google Scholar
• Bruckert E Hayem G Dejager S Yau C Begaud B Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study Cardiovasc Drugs Ther 2005 19 6 403 414 16453090
   PubMed Web of Science ®Google Scholar
• Shanahan RL Kerzee JA Sandhoff BG Carroll NM Merenich JA Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization Pharmacotherapy 2005 25 3 345 351 15843281
   PubMed Web of Science ®Google Scholar
• Harper CR Jacobson TA The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis Curr Opin Lipidol 2007 18 4 401 408 17620856
   PubMed Web of Science ®Google Scholar
• Toth PP Harper CR Jacobson TA Clinical characterization and molecular mechanisms of statin myopathy Expert Rev Cardiovasc Ther 2008 6 7 955 969 18666846
   PubMedGoogle Scholar
• Molokhia M McKeigue P Curcin V Majeed A Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006 PLoS ONE 2008 3 6 e2522 18575628
   PubMed Web of Science ®Google Scholar
• Newman C Tsai J Szarek M Luo D Gibson E Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients Am J Cardiol 2006 97 1 61 67 16377285
   PubMed Web of Science ®Google Scholar
• Wiviott SD Cannon CP Morrow DA Ray KK Pfeffer MA Braunwald E Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy J Am Coll Cardiol 2005 46 8 1411 1416 16226163
   PubMed Web of Science ®Google Scholar
• Davidson MH Robinson JG Safety of aggressive lipid management J Am Coll Cardiol 2007 49 17 1753 1762 17466224
   PubMed Web of Science ®Google Scholar
• Hodel C Myopathy and rhabdomyolysis with lipid-lowering drugs Toxicol Lett 2002 128 1–3 159 168 11869826
   PubMed Web of Science ®Google Scholar
• Marcoff L Thompson PD The role of coenzyme Q10 in statin associated myopathy: a systematic review J Am Coll Cardiol 2007 49 23 2231 2237 17560286
   PubMed Web of Science ®Google Scholar
• Flint OP Masters BA Gregg RE Durham SK Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro Toxicol Appl Pharmacol 1997 145 1 91 98 9221828
   PubMed Web of Science ®Google Scholar
• Laaksonen R Jokelainen K Sahi T Tikkanen MJ Himberg JJ Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans Clin Pharmacol Ther 1995 57 1 62 66 7828383
   PubMed Web of Science ®Google Scholar
• Dirks AJ Jones KM Statin-induced apoptosis and skeletal myopathy Am J Physiol Cell Physiol 2006 291 6 C1208 C1212 16885396
   PubMed Web of Science ®Google Scholar
• Guijarro C Blanco-Colio LM Ortego M 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture Circ Res 1998 83 5 490 500 9734471
   PubMed Web of Science ®Google Scholar
• Mohaupt MG Karas RH Babiychuk EB Association between statin-associated myopathy and skeletal muscle damage Can Med Assoc J 2009 181 1–2 E11 E18 19581603
   PubMed Web of Science ®Google Scholar
• Sirvent P Mercier J Vassort G Lacampagne A Simvastatin triggers mitochondria-induced Ca2= signaling alteration in skeletal muscle Biochem Biophys Res Commun 2005 329 3 1067 1075 15752763
   PubMed Web of Science ®Google Scholar
• Group SC Link E Parish S SLCO1B1 variants and statin-induced myopathy – a genome wide study N Engl J Med 2008 359 8 789 799 18650507
   PubMed Web of Science ®Google Scholar
• Cash J Callender ME McDougall NI Young IS Nicholls DP Statin safety and chronic liver disease Int J Clin Pract 2008 62 12 1831 1835 19166430
   PubMed Web of Science ®Google Scholar
• Cohen D Anania F Chalasani N An assessment of statin safety by hepatologists Am J Cardiol 2006 97 8A 77C 81C 16377288
   PubMed Web of Science ®Google Scholar
• Pasternak RC Smith SCJr Bairey-Merz CN Grundy SM Cleeman JI Lenfant C ACC/AHA/NHLBI clinical advisory on the use and safety of statins Circulation 2002 106 8 1024 1028 12186811
   PubMed Web of Science ®Google Scholar
• Argo CK Loria P Caldwell SH Lonardo A Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008 48 2 662 669 18666246
   PubMed Web of Science ®Google Scholar
• Calderon RM Luigi X Cubeddu LX Goldberg RB Schiff ER Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma Mayo Clin Proc 2010 85 4 349 356 20360293
   PubMed Web of Science ®Google Scholar
• De Denus S Spinler SA Miller K Peterson AM Statins and liver toxicity: a meta-analysis Pharmacotherapy 2004 24 5 584 591 15162892
   PubMed Web of Science ®Google Scholar
• Kornbrust DJ MacDonald JS Peter CP Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits J Pharmacol Exp Ther 1989 248 2 498 505 2918466
   PubMed Web of Science ®Google Scholar
• Dale KM White CM Henyan NN Kluger J Coleman CI Impact of statin dosing intensity on transaminase and creatine kinase Am J Med 2007 120 8 706 712 17679130
   PubMed Web of Science ®Google Scholar
• Pasanen MK Fredrikson H Neuvonen PJ Niemi M Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin Clin Pharmacol Ther 2007 82 6 726 733 17473846
   PubMed Web of Science ®Google Scholar
• Chalasani N Statins and hepatotoxicity: focus on patients with fatty liver Hepatology 2005 41 4 690 695 15789367
   PubMed Web of Science ®Google Scholar
• Athyros VG Tziomalos K Gossios TD GREACE Study Collaborative Group Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis Lancet 2010 376 9756 1916 1922 21109302
   PubMed Web of Science ®Google Scholar
• Tolman KG The liver and lovastatin Am J Cardiol 2002 89 12 1374 1380 12062731
   PubMed Web of Science ®Google Scholar
• Cziraky MJ Willey VJ McKenney JM Statin safety: an assessment using an administrative claims database Am J Cardiol 2006 97 8A 61C 68C 16377285
   PubMed Web of Science ®Google Scholar
• Bhardwaj SS Chalasani N Lipid lowering agents that cause drug induced hepatotoxicity Clin Liver Dis 2007 11 3 597 613 17723922
   PubMedGoogle Scholar
• Clarke AT Mills PR Atorvastatin associated liver disease Dig Liver Dis 2006 38 10 772 777 16777499
   PubMedGoogle Scholar
• Castiella A Fernandez J Zapata E Autoimmune hepatitis after treatment with fluvastatin Liver Int 2007 27 4 592 17403199
   PubMed Web of Science ®Google Scholar
• Wolters LM Van Buuren HR Rosuvastatin-associated hepatitis with autoimmune features Eur J Gastroenterol Hepatol 2005 17 5 589 590 15827453
   PubMed Web of Science ®Google Scholar
• Pelli N Setti M Atorvastatin as a trigger of autoimmune hepatitis J Hepatol 2004 40 4 716 15030994
   PubMed Web of Science ®Google Scholar
• Grattagliano I Portincasa P Palmieri VO Palasciano G Overview on the mechanisms of drug-induced liver cell death Ann Hepatol 2002 1 4 162 168 15280801
   PubMedGoogle Scholar
• Anfossi G Massucco P Bonomo K Trovati M Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits Nutr Metab Cardiovasc Dis 2004 14 4 215 224 15553600
   PubMed Web of Science ®Google Scholar
• Hansen KE Hildebrand JP Ferguson EE Stein JH Outcomes in 45 patients with statin-associated myopathy Arch Intern Med 2005 165 22 2671 2676 16344427
   PubMedGoogle Scholar
• Glueck CJ Aregawi D Agloria M Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies Clin Ther 2006 28 6 933 942 16860175
   PubMed Web of Science ®Google Scholar
• Rindone JP Achacoso R Bledsoe R Effect of lovastatin administered every other day on serum low density ipoprotein cholesterol >160 mg/dl Am J Cardiol 1995 76 4 312 313 7618632
   PubMed Web of Science ®Google Scholar
• Dennis VC Britton ML Sirmans SM Letassy NA Freeman DA The use of alternate-day lovastatin in hypercholesterolemic men Ann Pharmacother 1997 31 6 708 712 9184709
   PubMed Web of Science ®Google Scholar
• Rindone JP Hiller D Arriola G A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia Pharmacotherapy 1998 18 4 836 839 9692657
   PubMed Web of Science ®Google Scholar
• Copher HR Steward RD Daily dosing versus alternate-dosing of simvastatin in patients with hypercholesterolemia Pharmacotherapy 2002 22 9 1110 1116 12222546
   PubMed Web of Science ®Google Scholar
• Lennerna SH Clinical pharmacokinetics of atorvastatin Clin Pharmacokinet 2003 42 13 1141 1160 14531725
   PubMed Web of Science ®Google Scholar
• Lins RL Matthys KE Verpooten GA Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients Nephro Dial Transplant 2003 18 5 967 976
   Web of Science ®Google Scholar
• Piamsomboon C Laothavorn P Saguonwong S Chatloong B Nasawadi C Tanprasert P Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia J Med Assoc Thai 2002 85 3 297 300 12117017
   PubMedGoogle Scholar
• Juszczyk MA Seip RL Thompson PD Decreasing LDL cholesterol and medication cost with every-other-day statin therapy Prev Cardiol 2005 8 4 197 199 16230873
   PubMedGoogle Scholar
• Matalka MS Ravnan MC Deedwania MD Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day versus Daily Dosing of Atrovastatin Study (ADDAS) Am Heart J 2002 144 4 674 677 12360164
   PubMed Web of Science ®Google Scholar
• Jafari M Ebrahimi R Ahmadi-Kashani M Balian H Bashir M Efficacy of alternate-day dosing versus daily dosing of atorvastatin J Cardiovasc Pharmacol Ther 2003 8 2 123 126 12808485
   PubMedGoogle Scholar
• Keles T Akar Bayram N Kayhan T The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels Anadolu Kardiyol Derg 2008 8 6 407 412 19103535
   PubMedGoogle Scholar
• Ferrer-Garcia JC Perez-Silvestre J Martinez-Mir I Herrera-Ballester A Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidemia Acta Diabetol 2006 43 3 75 78 17143784
   PubMed Web of Science ®Google Scholar
• Mackie BD Satija S Nell C Miller J Sperling LS Monday, Wednesday and Friday dosing of rosuvastatin in patients intolerant to statin therapy Am J Cardiol 2007 99 2 291 17223437
   PubMed Web of Science ®Google Scholar
• Bakes JM Vernero CV Gibson CA Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance Ann Pharmacother 2008 42 3 341 346 18285559
   PubMed Web of Science ®Google Scholar
• Wongwiwatthananukit S Sansanayudh N Dhummauppakorn R Kitiyadisai C Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia Ann Pharmacother 2006 40 11 1917 1923 17003082
   PubMed Web of Science ®Google Scholar
• Gadarla M Kearns AK Thompson PD Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins Am J Cardiol 2008 101 12 1747 1748 18549851
   PubMed Web of Science ®Google Scholar
• Backes JM Moriarty PM Ruisinger JF Gibson CA Effects of once weekly rosuvastatin among patients with a prior statin intolerance Am J Cardiol 2007 100 3 554 555 17659946
   PubMed Web of Science ®Google Scholar
• Ruisinger JF Backs JM Gibson CA Moriarty PM Once a week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance Am J Cardiol 2009 103 3 393 394 19166695
   PubMed Web of Science ®Google Scholar
• Athyros VG Tziomalos K Kakafika AI Koumaras H Karagiannis A Mikhailidis DP Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients Am J Cardiol 2008 101 4 483 485 18312762
   PubMed Web of Science ®Google Scholar
• Davidson MH Donovan JM Misir S Jones MR A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia Am J Cardiovasc Drugs 2010 10 5 305 314 20860413
   PubMed Web of Science ®Google Scholar
• Pandor A Ara RM Tumur I Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials J Intern Med 2009 265 5 568 580 19141093
   PubMed Web of Science ®Google Scholar
• Gazi IF Daskalopoulou SS Nair DR Mikhailidis DP Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin Curr Med Res Opin 2007 23 9 2183 2192 17692154
   PubMed Web of Science ®Google Scholar
• Rivers SM Kane MP Busch RS Bakst G Hamilton RA Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance Endocr Pract 2007 13 1 11 16 17360295
   PubMedGoogle Scholar
• Elam M Lovato LC Ginsberg H Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective Curr Opin Lipidol 2011 22 1 55 61 21102326
   PubMed Web of Science ®Google Scholar
• McKenney JM Farnier M Lo KW Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia J Am Coll Cardiol 2006 47 8 1584 1587 16630994
   PubMed Web of Science ®Google Scholar
• Brooks EL Kuvin JT Karas RH Niacin’s role in the statin era Expert Opin Pharmacother 2010 11 14 2291 2300 20569085
   PubMed Web of Science ®Google Scholar
• Canner PL Berge KG Wenger NK Fifteen year mortality in coronary drug project patients: long-term benefit with niacin J Am Coll Cardiol 1986 8 6 1245 1255 3782631
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH Nessim SA Johnson RL Sanmarco ME Azen SP Cashin-Hemphill L Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 1987 257 23 3233 3240 3295315
   PubMed Web of Science ®Google Scholar
• Brown G Albers JJ Fisher LD Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 1990 323 19 1289 1298 2215615
   PubMed Web of Science ®Google Scholar
• Duggal JK Singh M Attri N Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease J Cardiovasc Pharmacol Ther 2010 15 2 158 166 20208032
   PubMed Web of Science ®Google Scholar
• Labreuche J Deplanque D Touboul PJ Bruckert E Amarenco P Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis Atherosclerosis 2010 212 1 9 15 20457452
   PubMed Web of Science ®Google Scholar
• Jenkins DJ Kendall CW Marchie A Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein JAMA 2003 290 4 502 510 12876093
   PubMed Web of Science ®Google Scholar
• Ma J Li Y Ye Q Constituents of red yeast rice, a traditional Chinese food and medicine J Agric Food Chem 2000 48 11 5220 5225 11087463
   PubMed Web of Science ®Google Scholar
• Becker DJ Gordon RY Halbert SC French B Morris PB Rader D Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial Ann Intern Med 2009 150 12 830 839 19528562
   PubMed Web of Science ®Google Scholar
• Halbert SC French B Gordon RY Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance Am J Cardiol 2010 105 2 198 204 20102918
   PubMed Web of Science ®Google Scholar
• Venero CV Venero JV Wortham DC Thompson PT Lipid-lowering efficacy of red yeast rice in a population intolerant to statins Am J Cardiol 2010 105 5 664 666 20185013
   PubMed Web of Science ®Google Scholar
• Cicero AFG Derosa G Bove M Imola F Borghi C Gaddi AV Long-term effectiveness and safety of a nutraceuticals-based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome Curr Top Nutraceutical Res 2009 3–4 121 126
   Web of Science ®Google Scholar
• Caso G Kelly P McNurlan MA Lawson WE Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins Am J Cardiol 2007 99 10 1409 1412 17493470
   PubMed Web of Science ®Google Scholar
• Erkal MZ Wilde J Bilgin Y High prevalence of vitamin D deficiency, secondary hyperparathyroidism and generalized bone pain in Turkish immigrants in Germany: identification of risk factors Osteoporos Int 2006 17 8 1133 1140 16718398
   PubMed Web of Science ®Google Scholar
• Ahmed W Khan N Glueck CJ Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis myalgia in statin-treated patients Transl Res 2009 153 1 11 16 19100953
   PubMed Web of Science ®Google Scholar